3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
3
Phase 2/3
1
Phase 1
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
2
Other hematologic neoplasm
2
Plasma cell
1
Myeloid
1
Lymphoid
1
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Endocrine
1
Dermatologic
1
CNS
1
Conditions
Thyroid Carcinoma, Anaplastic
1
Thyroid Cancer, Papillary
1
Ovarian Neoplasms
1
Neoplasms by Site
1
Neoplasms by Histologic Type
1
Neoplasms
1
Multiple Myeloma
1
Melanoma
1
Laryngeal Neoplasms
1
Hematologic Neoplasms
1
Glioma
1
Erdheim-Chester Disease
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
lutetium Lu 177 dotatate
2
Fluorouracil
2
Everolimus
2
trametinib
1
toripalimab
1
fosbretabulin
1
fluorocholine
1
dabrafenib
1
combretastatin
1
cobimetinib
1
anlotinib
1
Water
1
Vemurafenib
1
Testosterone
1
Temozolomide
1
Somatostatin
1
Sodium Iodide
1
Sodium Chloride
1
Sirolimus
1
Radiotherapy
1
Radiofrequency Ablation
1
Positron Emission Tomography Computed Tomography
1
Paclitaxel
1
PE regimen
1
Oxaliplatin
1
Magnetic Resonance Spectroscopy
1
Leucovorin
1
Injections
1
Erythromycin
1
EC regimen
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2/3
×
Vemurafenib
×
Endocrine
×
Clear all
NCT05768178
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
30 enrolled